Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Graves’ Disease
source: American Association for Clinical Chemistry (AACC)
year: 2021
summary/abstract:Graves disease is the most common cause of overactive thyroid (hyperthyroidism). It is an autoimmune disorder, an attack on the thyroid gland by a person’s own immune system. The thyroid gland is a butterfly-shaped organ that lies flat against the windpipe in the throat. It produces the hormones thyroxine (T4) and triiodothyronine (T3) and plays an important role in controlling the body’s metabolism.
Thyroid hormone production is normally regulated in a feedback mechanism that includes the pituitary gland, a pea-sized organ at the base of the brain. The pituitary produces thyroid-stimulating hormone (TSH), which in turn stimulates the production of T4 and T3. With Graves disease, an autoantibody called thyroid stimulating immunoglobulin (TSI) is produced. TSI acts like TSH and causes the thyroid gland to produce excess thyroid hormone. Over time, this can cause the thyroid gland to enlarge.
read more
Related Content
-
Thymic Hyperplasia Associated With Graves’ Disease: Pathophysiology and Proposed Management AlgorithmBackground: The association between Gra...
-
Radioiodine Ablation of Postsurgical Thyroid Remnants After Treatment With Recombinant Human TSH (rhTSH) in Patients...Context: Recent evidence suggests thyro...
-
Disease Presentation and Remission Rate in Graves’ Disease Treated With Antithyroid Drugs: Is Gender Really a ...Objective: Male gender is considered an...
-
Your Guide to Understanding Graves’ DiseaseGraves disease is a condition that affec...
-
Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Di...Graves’ disease is an autoimmune condi...
-
Factitious Graves’ Disease Due to Biotin Immunoassay Interference-A Case and Review of the LiteratureContext: Biotin (vitamin B7) is an esse...
-
Early Use of Steroid-Sparing Agents in the Inactivation of Moderate-to-Severe Active Thyroid eye DiseaseObjectives: The current first-line trea...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.